Organon & Co. Reports Q2 2026 Revenue Decline to $1.558 Billion

Organon & Co. reported its financial results for the second quarter of 2026, revealing a total revenue of $1.558 billion, a decrease of 2% compared to $1.594 billion in the same quarter of 2025. For the first half of 2026, revenues totaled $3.018 billion, down from $3.107 billion in the prior year. The company's net income for the second quarter was $108 million, or $0.40 per diluted share, compared to $145 million, or $0.56 per diluted share, in the same period last year. The decline in revenue and profitability was attributed to lower sales in key product lines, including Ontruzant and Singulair, as well as the absence of sales from the recently divested Jada System.

In terms of operational changes, Organon completed the divestiture of the Jada System to Laborie Medical Technologies in January 2026 for up to $465 million, which included a net gain of $81 million recognized in the first half of 2026. The company also entered into a definitive agreement with Sun Pharmaceutical Industries to acquire all outstanding shares for $14.00 per share, with stockholder approval received on July 23, 2026. This transaction is expected to close in early 2027, pending regulatory approvals.

Organon’s product performance showed mixed results across its portfolios. The Women’s Health segment saw a decline in sales for Nexplanon and Follistim AQ, primarily due to decreased physician demand and competitive pricing pressures. However, Hadlima, a biosimilar to Humira, experienced a significant sales increase of 59% in the second quarter, driven by stronger demand in the U.S. and Puerto Rico. Overall, the company reported a 4% decrease in sales for the first half of 2026, with international sales slightly outperforming U.S. sales.

The company’s operational metrics reflected a strategic focus on efficiency, with a reduction in selling, general, and administrative expenses by 4% in the second quarter. Research and development expenses also decreased by 5%, attributed to cost-saving measures and a reduction in clinical study activities. As of June 30, 2026, Organon reported cash and cash equivalents of $1.132 billion, an increase from $574 million at the end of 2025, bolstered by cash flow management strategies and the proceeds from the Jada divestiture.

Looking ahead, Organon anticipates continued challenges in the market, including pricing pressures and competition from generics as some products lose exclusivity. The company is adapting its business strategies to navigate these conditions while focusing on its core mission of improving women's health. The successful completion of the Sun Pharma transaction and ongoing collaborations, such as with Samsung Bioepis for biosimilars, are expected to play a crucial role in shaping the company's future growth trajectory.